Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 2A, Randomized, Double-Blind, Dose Ranging Study to Evaluate the Efficacy and Safety of VT-1161 Oral Tablets Compared to Fluconazole in the Treatment of Patients With Moderate to Severe Acute Vulvovaginal Candidiasis

Trial Profile

A Phase 2A, Randomized, Double-Blind, Dose Ranging Study to Evaluate the Efficacy and Safety of VT-1161 Oral Tablets Compared to Fluconazole in the Treatment of Patients With Moderate to Severe Acute Vulvovaginal Candidiasis

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 28 Aug 2020

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Oteseconazole (Primary) ; Fluconazole
  • Indications Vulvovaginal candidiasis
  • Focus Proof of concept; Therapeutic Use
  • Sponsors Viamet Pharmaceuticals
  • Most Recent Events

    • 26 Aug 2020 According to a Mycovia Pharmaceuticals media release, results from this study was peer-reviewed and published in Clinical Infectious Diseases, a journal of the Infectious Diseases Society of America.
    • 26 Aug 2020 Results presented in a Mycovia Pharmaceuticals media release.
    • 20 Aug 2020 Primary endpoint (Percentage of Subjects With Therapeutic Cure at 28 Days for All Analysis Population) has not been met according to the results published in the Clinical Infectious Diseases
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top